Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | MC4R | P32245 | 1/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 3/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22389607 | 1.00 | CYP2D6 (0.37) | CYP2D6MC4RSSTR4CYP2C19 | |
| SCHEMBL22389608 | 1.00 | CYP2D6 (0.37) | CYP2D6MC4RSSTR4CYP2C19 | |
| SCHEMBL22389609 | 1.00 | CYP2D6 (0.37) | CYP2D6MC4RSSTR4CYP2C19 | |
| SCHEMBL22235480 | 0.80 | FUCA1 (0.46) | SSTR4 | |
| SCHEMBL20660476 | 0.78 | CYP2D6 (0.39) | CYP2D6MC4R | |
| SCHEMBL19280968 | 0.78 | CYP2D6 (0.39) | CYP2D6MC4R | |
| SCHEMBL20660478 | 0.78 | CYP2D6 (0.39) | CYP2D6MC4R | |
| SCHEMBL22235538 | 0.78 | ITGB3 (0.31) | MC4R | |
| SCHEMBL19280966 | 0.78 | CYP2D6 (0.39) | CYP2D6MC4R | |
| SCHEMBL4182300 | 0.78 | CYP2D6 (0.39) | CYP2D6MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230278987-A1 | Antimicrobial Compounds and Methods | CURZA GLOBAL, LLC. | 2023-09-07 | — | — | US | disclosed |
| EP-3654968-B1 | METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2023129963-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | CURZA GLOBAL, LLC (US) | 2023-07-06 | — | — | WO | disclosed |
| US-20230072397-A1 | Antimicrobial Compounds and Methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-03-09 | — | — | US | disclosed |
| WO-2022253309-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND APPLICATION THEREOF | 首药控股(北京)股份有限公司 | 2022-12-08 | — | — | WO | disclosed |
| EP-3911643-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | Curza Global LLC (US) | 2021-11-24 | — | — | EP | disclosed |
| WO-2021097061-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | CURZA GLOBAL, LLC (US) | 2021-05-20 | — | — | WO | disclosed |
| WO-2020150372-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | CURZA GLOBAL, LLC (US) | 2020-07-23 | — | — | WO | disclosed |
| US-7932246-B2 | Histone deacetylase inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-04-26 | — | — | US | disclosed |
| EP-1881977-B1 | HISTONE DEACETYLASE INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2011-01-05 | — | — | EP | disclosed |
| US-20100152155-A1 | Histone Deacetylase Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278987-A1 | Antimicrobial Compounds and Methods | CLPP, RPN2, MPO | CYP2D6 2117/4885MC4R 4759/4885SSTR4 4583/4885 |
| US-20230072397-A1 | Antimicrobial Compounds and Methods | MPO, NISCH, RPN2 | CYP2D6 1521/4885MC4R 4501/4885SSTR4 4409/4885 |
| US-20100152155-A1 | Histone Deacetylase Inhibitors | HDAC1, HDAC2, HDAC11 | CYP2D6 2179/4885MC4R 4091/4885SSTR4 4330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.